

sub
CS
to
BC

accordance with claim 33, wherein said therapeutic avenues regulate the presence or absence of the biopolymer including the sequence ^{Consisting of} ~~identified as~~ SEQ ID NO: 1 or at least one analyte thereof.

C

35. A process for regulating ^{myocardial infarction or renal failure} ~~a disease state~~ by controlling the presence or absence of a ^{Consisting of} ~~identified as~~ biopolymer including the sequence ~~identified as~~ SEQ ID NO: 1 or at least one analyte thereof.

REMARKS

The foregoing Supplemental Preliminary Amendment is made so as to further bring this application into conformance with Rules 37 CFR §1.821 - 1.825. No new matter is added. Examination on the merits is respectfully requested.

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE SPECIFICATION:

Page 27, line 18, replace "identified by the sequence SESDFLAEGGGVR" with --having a sequence identified as SEQ ID NO: 1--.

IN THE CLAIMS:

Claim 1, lines 1-2, replace "the sequence ID SESDFLAEGGGVR" with --having a sequence identified as SEQ ID NO: 1--.

Claim 17, line 2, replace "ID SESDFLAEGGGVR" with --identified as SEQ ID NO: 1--.

Claim 18, line 6, replace "ID SESDFLAEGGGVR" with --identified as SEQ ID NO: 1--.

Claim 25, line 2, replace "ID SESDFLAEGGGVR" with --identified as SEQ ID NO: 1--.

Claim 29, line 2, replace "sequence ID SESDFLAEGGGVR" with --having a sequence identified as SEQ ID NO: 1.

Claim 30, line 2, replace "ID SESDFLAEGGGVR" with --identified as SEQ ID NO: 1--.

Claim 33, lines 4-5, replace "ID SESDFLAEGGGVR" with --identified as SEQ ID NO: 1--.

Claim 34, line 4, replace "ID SESDFLAEGGGVR" with --identified as SEQ ID NO: 1--.

Claim 35, lines 2-3, replace "ID SESDFLAEGGGVR" with --identified as SEQ ID NO: 1--.

Date:

4/19/2002

Respectfully submitted,

Ferris H. Lander

Ferris H. Lander

Registration No. 43,377

McHale & Slavin, P.A.

4440 PGA Boulevard, Suite 402

Palm Beach Gardens, FL 33410

Telephone: (561) 625-6575